Levofloxacin Tablets

Active Ingredients: Levofloxacin HCl

Levofloxacin HCl Tablets are an antibiotic drug used to treat bacterial infections of the throat, ear, mouth, or urinary tract. It may be used to treat bacterial infections that cannot be treated with other antibiotics.

Levofloxacin is also used as a prophylactic treatment in potential anthrax and plague exposures.

Levofloxacin HCl can also be used as eye drops to treat cases of bacterial eye infections.

Levofloxacin is classified as a fluoroquinolone antibiotic that works by blocking bacteria from reproducing. It exerts its antimicrobial activity via the inhibition of bacterial enzymes DNA gyrase and topoisomerase IV. DNA gyrase is only found in bacteria and is essential for chromosome condensation and the initiation of transcription and topoisomerase IV is essential for DNA replication and cell division. Levofloxacin’s inhibition of these enzymes prevents bacterial cell division and results in cell death.

AdvaCare Pharma is a manufacturer and exporter of Levofloxacin Tablets. We offer a wide range of high-quality and cost-effective medications that are available for distribution. Our medications are produced in our GMP-certified facilities in China, India, and the USA.

We are a Levofloxacin manufacturer engaged in the global distribution of 200+ oral solid pharmaceutical products in tablet dosage form.

As an American-owned and operated company, we are devoted to the manufacture and supply of superior quality, yet cost-effective pharmaceuticals to improve access to healthcare solutions worldwide. AdvaCare Pharma manufactures Levofloxacin Tablets, and over 500 other pharmaceutical treatments, according to strict GMP regulations as part of our global commitment to bring efficacious medicines to pharmaceutical distributors, hospitals, pharmacies and other medical institutions.

What is Levofloxacin HCl used for?

It is also used to prevent plague or anthrax infection after exposures.

How should Levofloxacin HCl Tablets be used?

This medication is intended to be taken orally. Levofloxacin HCl Tablets can be taken with or without food.

Food, beverages, medications, or supplements containing magnesium, aluminum, sucralfate, iron, zinc, or calcium should not be consumed 2 hours before or 6 hours after taking levofloxacin, as they can reduce its efficacy.

Drink fluids liberally for the duration of treatment to combat dehydration and the potential formation of urine crystals.

What dose should be taken and for how long?

The recommended adjustments are as follows:

Children (≥ 50kg) Post-exposure inhalation of anthrax: the recommended dose is 500mg once daily for 60 days. Treatment should be initiated as soon as possible after suspected or confirmed exposure.

Post-exposure or infection due to Y. pestis: the recommended dose is 500mg once daily for 10-14 days. Treatment should be initiated as soon as possible after suspected or confirmed exposure.

Children (30 - 49kg) Post-exposure inhalation of anthrax: the recommended dose is 250mg twice daily for 60 days. Treatment should be initiated as soon as possible after suspected or confirmed exposure.

Post-exposure or infection due to Y. pestis: the recommended dose is 250mg twice daily for 10-14 days. Treatment should be initiated as soon as possible after suspected or confirmed exposure.

Levofloxacin’s safety for adult treatments lasting longer than 28 days or pediatric treatments lasting longer than 14 days have not been studied.

The dosage is based on medical condition, response to treatment, age, and weight. Refer to a doctor or pharmacist for guidelines on dosage. Do not exceed what they advise.

What if a dose is missed?

If a dose is missed, it should be taken no later than 6 hours before the next scheduled dose. If it is less than 6 hours before the next dose, skip the missed dose and resume treatment as prescribed. Do not take double doses to compensate for a missed dose.

Who can use Levofloxacin?

Levofloxacin can be administered to adults and children, but caution is advised for specific groups of patients.

Pregnant Animal studies have not revealed evidence of teratogenic effects from levofloxacin doses at about 1-9 times the maximum recommended human dose.

Current human data have not identified a connection between levofloxacin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes. While there is no definitive conclusion, the risk cannot be ruled out. The potential clinical benefits and risks should be considered before using levofloxacin during pregnancy.

Nursing Levofloxacin is excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, either nursing or levofloxacin should be discontinued, based on the importance of the drug to the patient. Patients should wait an additional 2 days after levofloxacin discontinuation before resuming nursing. In cases of anthrax exposure, the benefit of nursing while on levofloxacin therapy may warrant the risk.

Levofloxacin Tablets are produced at higher doses and should not be administered to pediatric patients who weigh < 30kg. Intravenous (IV) formulations of levofloxacin, such as Levofloxacin Lactate Injection, are recommended for pediatric patients weighing less than 30kg.

Pediatric patients receiving levofloxacin are at an increased risk of developing musculoskeletal disorders, such as arthralgia, arthritis, tendinopathy, and gait abnormalities.

Geriatric Studies with adults ≥ 65 years have not found differences in the safety or efficacy of levofloxacin use in older adults compared to younger adults.

There were no differences in clinical experiences, but a greater sensitivity to medications cannot be ruled out.

Geriatric patients treated with fluoroquinolones, like levofloxacin, have a greater risk for developing severe tendon disorders. This risk is further increased with concomitant corticosteroid therapy.

An increased incidence of aortic aneurysm and dissection up to 2 months following fluoroquinolone use in older patients has been reported.

Other warnings

In patients with renal insufficiency, levofloxacin should be administered with caution and a dosage reduction may be necessary.

In patients with hepatic insufficiency, hepatotoxicity resulting in acute hepatitis and fatalities have been reported. Dosage reductions may be necessary.

Fluoroquinolones, including levofloxacin, have also been associated with the onset or exacerbation of myasthenia gravis, photosensitivity/phototoxicity, and diabetes mellitus.

As with all pharmaceutical medicines, some unwanted effects can occur from the use of Levofloxacin HCl Tablets.

For a comprehensive understanding of all potential side effects, consult a medical professional.

If any symptoms persist or worsen, or you notice any other symptoms, please call your doctor immediately.

Due to possible drug interactions, consult with your doctor about any medications you are taking before your treatment.

Levofloxacin in the treatment of community-acquired pneumonia

Levofloxacin has a broad spectrum of activity against several causative bacterial pathogens of community-acquired pneumonia (CAP). This study evaluated the efficacy and tolerability of levofloxacin 500mg once daily for 10 days in patients with CAP.

A high-dose (750mg), short-course (5 days) of once-daily levofloxacin has been approved for use in the USA in the treatment of CAP. It can also be used for treating acute bacterial sinusitis, acute pyelonephritis, and complicated urinary tract infections.

The conclusion of this study is that levofloxacin is rapidly absorbed and is bioequivalent to the intravenous formulation. This drug is well tolerated and has good tissue penetration and adequate concentrations.